These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 27123918)

  • 1. Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy.
    Soliman AM; Bonafede M; Farr AM; Castelli-Haley J; Winkel C
    J Manag Care Spec Pharm; 2016 May; 22(5):573-87. PubMed ID: 27123918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-back therapy use and its impact on LA persistence in patients with endometriosis.
    Fuldeore MJ; Marx SE; Chwalisz K; Smeeding JE; Brook RA
    Curr Med Res Opin; 2010 Mar; 26(3):729-36. PubMed ID: 20092387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of subsequent surgery rates among endometriosis patients who underwent surgery with and without concomitant leuprolide acetate therapy.
    Soliman AM; Bonafede M; Farr AM; Castelli-Haley J; Winkel C
    Curr Med Res Opin; 2016 Jun; 32(6):1073-82. PubMed ID: 27027333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
    DiVasta AD; Feldman HA; Sadler Gallagher J; Stokes NA; Laufer MR; Hornstein MD; Gordon CM
    Obstet Gynecol; 2015 Sep; 126(3):617-627. PubMed ID: 26181088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).
    Donnez J; Becker C; Taylor H; Carmona Herrera F; Donnez O; Horne A; Paszkowski M; Petraglia F; Renner SP; Patel A; Boolell M; Bestel E; Dolmans MM
    Hum Reprod; 2024 Jun; 39(6):1208-1221. PubMed ID: 38648863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.
    Hornstein MD; Surrey ES; Weisberg GW; Casino LA
    Obstet Gynecol; 1998 Jan; 91(1):16-24. PubMed ID: 9464714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.
    Chwalisz K; Surrey E; Stanczyk FZ
    Reprod Sci; 2012 Jun; 19(6):563-71. PubMed ID: 22457429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health Care Utilization and Costs Associated with Endometriosis Among Women with Medicaid Insurance.
    Soliman AM; Surrey ES; Bonafede M; Nelson JK; Vora JB; Agarwal SK
    J Manag Care Spec Pharm; 2019 May; 25(5):566-572. PubMed ID: 31039061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.
    Surrey ES; Hornstein MD
    Obstet Gynecol; 2002 May; 99(5 Pt 1):709-19. PubMed ID: 11978277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.
    Surrey ES; Voigt B; Fournet N; Judd HL
    Fertil Steril; 1995 Apr; 63(4):747-55. PubMed ID: 7890057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [No Abstract]   [Full Text] [Related]  

  • 13. Gonadotropin-releasing hormone agonist plus estrogen-progestin "add-back" therapy for endometriosis-related pelvic pain.
    Friedman AJ; Hornstein MD
    Fertil Steril; 1993 Aug; 60(2):236-41. PubMed ID: 8339817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Effects of Gonadotropin-Releasing Hormone Agonists and Add-Back in Adolescent Endometriosis.
    Gallagher JS; Missmer SA; Hornstein MD; Laufer MR; Gordon CM; DiVasta AD
    J Pediatr Adolesc Gynecol; 2018 Aug; 31(4):376-381. PubMed ID: 29551430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
    Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome.
    Mitwally MF; Gotlieb L; Casper RF
    Menopause; 2002; 9(4):236-41. PubMed ID: 12082359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial.
    Sadler Gallagher J; Feldman HA; Stokes NA; Laufer MR; Hornstein MD; Gordon CM; DiVasta AD
    J Pediatr Adolesc Gynecol; 2017 Apr; 30(2):215-222. PubMed ID: 26927501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Initiation Patterns, Modifications, and Medication Adherence Among Newly Diagnosed Heart Failure Patients: A Retrospective Claims Database Analysis.
    Deschaseaux C; McSharry M; Hudson E; Agrawal R; Turner SJ
    J Manag Care Spec Pharm; 2016 May; 22(5):561-71. PubMed ID: 27123917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis.
    Divasta AD; Laufer MR; Gordon CM
    J Pediatr Adolesc Gynecol; 2007 Oct; 20(5):293-7. PubMed ID: 17868896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.